deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT00177853

Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

A Phase I Study of Celecoxib, Irinotecan and Concurrent Radiotherapy in the Preoperative Treatment of Pancreatic Cancer

Sponsor: Pharmacia and Upjohn

Conditions Pancreatic Cancer
Interventions celecoxib concurrent radiotherapy irinotecan
Updated 7 times since 2017 Last updated: Jul 1, 2010 Started: Dec 31, 2006 Primary completion: Dec 31, 2006 Completion: Jul 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

terminated

A PHASE1 clinical study on Pancreatic Cancer, this trial is terminated or withdrawn. The trial is conducted by Pharmacia and Upjohn and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Study Description(click to expand)

The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.

The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 19 months · monthly snapshotTerminated~Jan 2026 – present · 3 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Present [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pharmacia and Upjohn
  • University of Pittsburgh
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations